PERTH, Australia – Startup Inventia Life Science Pty. Ltd. has received two major investments from the Australian government to accelerate the development of a robotic device that prints a patient’s own skin cells directly onto a burn or wound. Named Ligō from the Latin “to bind,” the device could revolutionize the way surgeons approach wound repair.

Uncontrolled bleeding after giving birth is a common cause of severe maternal complications and even death, particularly in the U.S. and some developing nations. Alydia Health Inc. has developed a suction device that is placed in the uterus and is designed to halt hemorrhaging within a few minutes.

Liquid biopsy startup Thrive Earlier Detection Corp. has raised $257 million in a series B round led by Casdin Capital and Section 32. The funds will be used to finalize the design of its first product, Cancerseek, conduct a trial to support U.S. FDA approval and prepare for commercialization.

Mantra Bio Inc., of San Francisco, plans to take its new $25 million series A financing and advance its pipeline and partnering efforts for engineering targeted exosome vehicles. The company platform integrates computational approaches, wet biology and robotics to leverage exosome diversity and enable rational design of therapeutics for a range of tissue and cellular targets.

Nura Bio Inc., a company working to discover and develop new neuroprotective medicines, has closed a $73 million series A financing that President and CEO Alpna Seth said would help her team advance a multitarget pipeline, initially led by an inhibitor of the sterile alpha TIR motif protein 1 inhibitor (SARM1).